Top

Published in:

01-03-2013 | Original Article

The spectrum of urological malignancy in Lynch syndrome

Authors: P. J. Barrow, S. Ingham, C. O’Hara, K. Green, I. McIntyre, F. Lalloo, J. Hill, D. G. Evans

Published in: Familial Cancer | Issue 1/2013

Abstract

Urological tumours are the third most frequent malignancy in Lynch syndrome after colonic and endometrial cancer. Upper urinary tract tumours are well recognised in Lynch syndrome, but the association with prostate and bladder cancer is controversial. We determined the incidence and cumulative and relative risks of prostate and bladder cancer in a cohort of Lynch syndrome families. Male Lynch syndrome mutation carriers and their genetically untested male first degree relatives (FDR) were identified from the Manchester Regional Lynch syndrome database (n = 821). Time to the development of urological cancer was identified for each urological site (renal pelvis, ureter, bladder and prostate). Cumulative and relative risks were calculated, with results classified by mutation carrier status and specific causative genetic mutations. Eight prostate cancers were identified, only one occurring before the age of 60. Analysis of person-years at risk of prostate cancer by Lynch syndrome mutation carrier status suggests a correlation between MSH2 mutation carriers and a tenfold increased risk of prostate cancer (RR 10.41; 95 % CI 2.80, 26.65). No such association was found with bladder cancer (RR 1.88; 95 % CI 0.21, 6.79). The association of upper urinary tract tumours with MSH2 and MLH1 mutations was confirmed. We have carried out the largest study of male Lynch syndrome mutation carriers to establish the risks of urological malignancy. A tenfold increased risk of prostate cancer is supported in MSH2 with mutation carriers having roughly double the risk of prostate cancer to FDRs. A trial of PSA testing in MSH2 carriers from 40 to 50 years may be justifiable.

Bonis PA, Trikalinos TA, Chung M, Chew P, Ip S, DeVine D et al. (2007) Hereditary Nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evidence report/technology assessment no. 150 (Prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022). AHRQ Publication No. 07-E008. Agency for Healthcare Research and Quality, Rockville

Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I et al (2007) Guidelines for the clinical management of lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353–362PubMedCrossRef

Cairns SR, Schofield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD et al (2010) Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59:666–690PubMedCrossRef

Roupret M, Yates DR, Comperat E, Cussenot O (2008) Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol 54:1226–1236PubMedCrossRef

Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J et al (2004) Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268PubMedCrossRef

Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F et al (2009) Cumulative lifetime incidence of extracolonic cancers in lynch syndrome: a report of 121 families with proven mutations. Clin Genet 75:141–149PubMedCrossRef

Watson P, Riley B (2005) The tumor spectrum in lynch syndrome. Fam Cancer 4:245–248PubMedCrossRef

Watson P, Vasen HFA, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ et al (2008) The risk of extra-colonic, extra-endometrial cancer in the lynch syndrome. Int J Cancer 123(2):444–449PubMedCrossRef

Vasen HFA, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G et al (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19(20):4074–4080PubMed

10.

Wagner DG, Gatalica Z, Lynch HT, Kohl S, Johansson SL, Lele SM (2010) Neuroendocrine-type prostatic adenocarcinoma with microsatellite instability in a patient with lynch syndrome. Int J Surg Pathol 18(6):550–553PubMed

11.

Bauer CM, Ray AM, Halstead-Nussloch BA, Dekker RG, Raymond VM, Gruber SB et al (2011) Hereditary prostate cancer as a feature of lynch syndrome. Fam Cancer 10(1):37–42PubMedCrossRef

12.

Grindedal EM, Moller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landro SM et al (2009) Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol Biomarkers Prev 18(9):2460–2467PubMedCrossRef

13.

Van der Post RS, Kiemeney LA, Ligtenberg MJL, Witjes JA, Hulsbergen-van de Kaa CA, Bodmer D et al (2010) Risk of urothelial bladder cancer in lynch syndrome is increased, in particular among msh2 mutation carriers. J Med Genet 47:464–470PubMedCrossRef

14.

Koornstra JJ, Mourits MJE, Sijmons RH, Leliveld AM, Hollema H, Kleibeuker JH (2009) Management of extracolonic tumours in patients with lynch syndrome. Lancet Oncol 10:400–408PubMedCrossRef

15.

Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S et al (2012) Radical prostatectomy versus observation for localised prostate cancer. NEJM 367(3):203–213PubMedCrossRef

16.

Hoffman RM (2011) Screening for prostate cancer. N Engl J Med 365(21):2013–2019PubMedCrossRef

17.

Breslow NE, Day NE (1987) Statistical methods in cancer research Vol II. The design and analysis of cohort studies (IARC Scientific Publication No 82). International Agency for Research on Cancer, Lyon

18.

Cancer Research UK (2009) Available from http://info.cancerresearchuk.org/cancerstats/mortality/cancerdeaths/#Top

19.

Soravia C, Van der Klift H, Brundler M, Blouin JL, Wijnen J, Hutter P et al (2003) Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumour spectrum. Am J Med Genet 121((A)):159–162CrossRef

20.

Bratt O (2000) Hereditary prostate cancer. Br J Urol 85:588–598

21.

Impact-study.com. Available from http://www.impact-study.com

22.

Fredriksson H, Ikonen T, Autio V, Matikainen MP, Helin HJ, Tammela TLJ et al (2006) Identification of germline MLH1 alterations in familial prostate cancer. Eur J Cancer 42:2802–2806PubMedCrossRef

23.

Chen Y, Wang J, Fraig MM, Metcalf J, Turner WR, Bissada NK et al (2001) Defects of DNA mismatch repair in human prostate cancer. Cancer Res 61:4112–4121PubMed

24.

Goeke T, Schulmann K, Engel C, Holinski-Feder E, Pagenstecher C, Schackert HK et al (2006) Genotype-phenotype comparison of german mlh1 and msh2 mutation carriers clinically affected with lynch syndrome: a report by the german hnpcc consortium. J Clin Oncol 24(26):4285–4292CrossRef

25.

Bermejo JL, Eng C, Hemminki K (2005) Cancer characteristics in swedish families fulfilling criteria for hereditary nonpolyposis colorectal cancer. Gastroenterology 129:1889–1899PubMedCrossRef

26.

Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP et al (2012) Colorectal and other cancer risks for carriers and non-carriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol 30(9):958–964PubMedCrossRef

Title: The spectrum of urological malignancy in Lynch syndrome
Authors: P. J. Barrow
S. Ingham
C. O’Hara
K. Green
I. McIntyre
F. Lalloo
J. Hill
D. G. Evans
Publication date: 01-03-2013
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 1/2013
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-012-9573-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Multiple small “imaging” branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia?

Psychosocial factors and uptake of risk-reducing salpingo-oophorectomy in women at high risk for ovarian cancer

The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study

10 rare tumors that warrant a genetics referral

The Fourth Birt–Hogg–Dubé Symposium, Cincinnati, USA, 28th–30th March, 2012

A novel missense mutation (N78D) in a family with von Hippel–Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts

Keynote webinar | Spotlight on antibody–drug conjugates in cancer